Skip to main content
Full access
Letters to the Editor
Published Online: 1 February 2019

Prazosin for Alcohol Use Disorder: Response to Kleinman and Ostacher

To the Editor: We thank Drs. Kleinman and Ostacher for their comments regarding our recent article reporting the results of a double-blind randomized trial comparing prazosin with placebo for individuals with an alcohol use disorder who do not have posttraumatic stress disorder.
Drs. Kleinman and Ostacher take issue with several aspects of the data analyses and presentation of the study’s results, but we believe their concerns are unfounded. First, we opted to focus our primary analyses on the period of time after the medication was titrated to what is presumed to be a therapeutic dose, and we included participants who completed the titration phase to ascertain the medication effects in this initial phase II trial of prazosin. We did, however, include information in the online supplementary material on the sensitivity analyses involving the whole sample throughout the medication phase, which, in contrast to what was stated in the letter to the editor from Drs. Kleinman and Ostacher, showed the same pattern of results as the posttitration models. We also reported details regarding additional sensitivity analyses in the online supplement, including the rigorous follow-up models using random slopes.
Second, Drs. Kleinman and Ostacher appear to confuse our dependent variable outcomes (i.e., number of heavy drinking days per week, number of drinks per week, and number of drinking days per week) with the analytic models we used and that were outlined in the “Daily interactive voice response data” subsection under the “Statistical Analysis” subheading. They incorrectly state that the condition-by-week interactions were exploratory outcomes, when in fact they refer to the a priori primary analytic models used and were patently not exploratory.
Third, concern was expressed that we did not include the a priori power analysis in the body of the article and that we indicated in ClinicalTrials.gov our target enrollment was 150. The CONSORT diagram included in the article shows that we enrolled 151 individuals in the study and that 92 met criteria for randomization. In the original grant we did estimate that, in light of our strong pilot data, 60 participants per cell would be more than sufficient to detect statistical significance with 80% power at an alpha of 0.05. Thus, it is possible we were somewhat underpowered, but nonetheless we did find a modest but clinically relevant effect of prazosin on the number of drinks per drinking day and heavy drinking.
Finally, Drs. Kleinman and Ostacher state that we did not include information about the three drinking outcomes in the abstract. Although we did not provide detailed means and standard deviations in that portion of the article, we believe we gave a fair overview of the pattern of results indicating an effect of prazosin such that it was associated with significantly greater reductions in drinks per drinking day and likelihood of heavy drinking relative to matched placebo.
We appreciate the opportunity to respond to the issues raised by Drs. Kleinman and Ostacher and hope that our clarification of those issues is of use to Journal readership.

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 165 - 166
PubMed: 30704279

History

Accepted: 19 November 2018
Published online: 1 February 2019
Published in print: February 01, 2019

Keywords

  1. Alcohol Use Disorder
  2. Prazosin
  3. Randomized Clinical Trial
  4. Alcohol Abuse

Authors

Details

Murray Raskind, M.D.
Center of Excellence in Substance Abuse Treatment and Education (Simpson, Saxon) and the Mental Illness Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle (Simpson, Raskind); Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle (Simpson, Saxon, Raskind).

Notes

Send correspondence to Dr. Simpson ([email protected]).

Funding Information

The authors’ disclosures accompany the original article.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share